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SaudiAbstract Introduction: Toxoplasma gondii (T. gondii) is an intracellular protozoan that can infect
all mammals, who serve as intermediate host. It causes congenital, neurological, eyes complications
and mild or asymptomatic infections in humans. Purpose of this study: To investigate not only the
prevalence of T. gondii, but also to ﬁnd out its genotyping using multiple sequential molecular
methods to predict exactly the precise genotyping of T. gondii among Saudi pregnant women.
Methods: A cross-sectional study was conducted using multi-stage methods. Initial stage involved
enrolment of 250 Saudi pregnant women from multi-centre healthcare and community based
settings in the capital of Saudi Arabia Riyadh. The second stage was embracement of the laboratory
investigation that included Enzyme immunoassay (ELISA), DNA extraction, PCR, nested-PCR
assay, and genotyping of the seropositive cases. Results: 203 women agreed to take part in our study
with a response rate of 81.2% (203/250). Using ELISA, we found that the prevalence of
Toxoplasma gondii IgG and IgM antibodies was 32.5% and 6.4%, respectively. We found that
29 samples (80.6%) were of genotype II; however 7 samples (19.4%) were of genotype III.
Conclusion: Deﬁning the population structure of T. gondii from Saudi Arabia has important impli-
cations for transmission, immunogenicity, pathogenesis, and in planning preventive strategies.
Relationship between such variation in structure and disease manifestation in pregnant women is
still difﬁcult to assess due to the role of host immune status and genetic background on the control
of infection, and of other parasitic features such as the infecting dose or parasite stage. Our ﬁnding
646 J. Alghamdi et al.of the genotyping of T. gondii might facilitate and inform future studies on comparative genomics
and identiﬁcation of genes that control important biological phenotypes including pathogenesis and
transmission among Saudi women.
ª 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Toxoplasma gondii (T. gondii) is a single-celled parasitic
organism that can infect most animals and birds. Because it
reproduces only in cats, wild and domestic felines are the par-
asite’s ultimate host (Kravetz and Federman, 2005). T. gondii
is the third greatest common reason of fatal food-borne infec-
tion in United States (Mead et al., 1999). It causes congenital,
neurological, eyes complications and minor or asymptomatic
infections in humans (Kong et al., 2012). During pregnancy,
primary infection, which is transmitted trans-placentally,
may cause congenital toxoplasmosis (Many and Koren,
2006). This includes a wide range of manifestations, extending
from mild chorioretinitis, which can present many years after
birth, to miscarriage, mental retardation, microcephaly, hydro-
cephalus and seizures (Kravetz and Federman, 2005). Hence,
early and accurate diagnosis of toxoplasmosis can be crucial
for the prevention and control of the disease, particularly in
individual who are at risk, such as pregnant women.
Diagnosing T. gondii is usually achieved by identifying the
parasite-speciﬁc antibodies in the serum with serological tech-
niques such as Enzyme-linked Immunosorbent Assay (ELISA)
and Immuno-ﬂuorescence Antibody Assay (IFA) (Zhang
et al., 2009; Lau et al., 2010). However, serology is very difﬁ-
cult to interpret in pregnant patients. Furthermore,
Polymerase chain reaction (PCR) methods have substantial
advancement for the detection of toxoplasmosis. Among these
techniques, nested-PCR has been proved as the most sensitive
diagnostic technique for the diagnosis of toxoplasmosis (Kong
et al., 2012). There are different strains of T. gondii with vari-
able genetic structure. Three genetically different types
(strains) of Toxoplasma gondii are known. These are type-I,
type-II and type-III. Due to their genetic differences, the three
types also differ in the mode of infection and the severity of
symptoms. Therefore, identifying the genetic type helps in
better understanding the disease and probably ﬁnding the proper
treatment (Fuentes et al., 2001). In this context, the identiﬁca-
tion of atypical strains is of clinical and epidemiological
importance because atypical strains are usually associated with
severe disease outcomes (Ajzenberg et al., 2010).
Approximately one-third of the global human population is
infected with this pathogenic parasite including populations in
Europe, South America, Africa and several Asian countries
(Fallahi et al., 2014). The prevalence of positive serology for
Toxoplasma varies in various regions and cultures. In Saudi
Arabia, prevalence studies showed that 29.5–35.6% of preg-
nant women were found to have T. gondii during pregnancy
(Ghazi et al., 2002; Al-Harthi et al., 2006). However, limited
studies have been conducted to explore the trend and genotyp-
ing of such infection among Saudi pregnant women. Hence,
the aim of this study was to investigate not only the prevalence
of T. gondii, but also to ﬁnd out its genotyping using multiplesequential molecular methods to predict exactly the precise
genotyping of T. gondii among Saudi pregnant women.
2. Materials and methods
A cross-sectional study was conducted using multi-stage meth-
ods over a period of 9 months of the year 2011. Initial stage
involved enrolment of 250 Saudi pregnant women from
multi-centre healthcare and community based settings in the
capital of Saudi Arabia Riyadh. These centres were selected
from different regions involving rural and urban areas in order
to maximize the variety of our sample. Participants were
selected using convenient sampling. They were approached
during waiting time for their antenatal care visits and
explained the study aim and objectives, and a written consent
was obtained accordingly. Inclusion criteria were pregnant
women, Saudi, and aged 15–45 years.
The second stage was embracement of the laboratory inves-
tigation that included Enzyme immunoassay (ELISA), DNA
extraction, PCR, nested-PCR assay, and genotyping of the
seropositive cases.2.1. Enzyme immunoassay
Blood samples were collected from the consented participants
(6 mm). Each blood sample was divided into two tubes (3 ml
each): one contained the EDTA (EDTA tube) for extracting
the DNA and the second one was a plane tube kept to extract
serum. The later samples were left for one hour at room temper-
ature until clotting is established. Thereafter, the tubes were
centrifuged for 10 min at a speed of 3000 cycles for 15 min.
The resulted serum was transferred then into a clean dry tube
(Eppendorf tube) and kept in under20 C for further analysis.
Speciﬁc IgG and IgM antibodies to T. gondii in the serum
were measured by the ELISA test following the method of
Engvall and his colleagues with the commercial
ENZYWELL TOXOPLASMA IgG and IgM KIT, and using
the BEP III system (Siemens Healthcare Diagnostics Products
GmbH, Marburg, Germany) according to the manufacturer’s
instructions (Engvall and Perlmann, 1971, 1972). The extinc-
tion value of calibrator identiﬁed the upper limit of the refer-
ence range of non-infected individual (Cut-off). Therewith,
the ﬁndings were evaluated quantitatively by calculating a
ratio of the extinction value of the control or patient samples
over the extinction value of the calibrator. If the absorbance
of the sample is higher than that of the Cut-off (>1.3 for
IgG and >1.2 for IgM), the sample was considered positive
for the presence of speciﬁc antibodies and negative if it was
<0.7 of IgG and <0.8 for IgM. In case of doubt or borderline
test results (0.7–1.3 for IgG and 0.8–1.2 for IgM), the test was
repeated.
Table 2 Primers used for ampliﬁcation for the B1gene.
Primers used for ampliﬁcation for B1 gene
B1F1 50-GGAACTGCATCCGTTCATGAG-30
BIR1 50-TCTTTAAAGCGTTCGTGGTC-30
B1F2 50-TGCATAGGTTGCAGTCACTG-30
B1R2 50-GGCGACCAATCTGCGAATACACC-30
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Extraction of DNA was conducted using 3 ml of blood, which
was collected in tubes containing EDTA using DNA Isolation
Kit (MagNA Pure LC Instrument, Roche Diagnostics,
GmbH, Mannheim, Germany) according to the manufac-
turer’s instructions (Wittwer et al., 1997). This was used to
isolate highly puriﬁed genomic DNA from the whole blood
samples. The isolation procedure was based on magnetic-
bead technology. The samples were analysed by incubation
with a special buffer containing a chaotropic salt and
Proteinase K. Magnetic Glass Particles (MGPs) were added
and the DNA is bound to their surfaces. Unbound substances
were removed by several washing steps, and then the puriﬁed
DNA was eluted with a low salt buffer. This was followed
by testing the purity of DNA. The purity and concentration
of the extracted DNA was determined using spectrophotome-
ter. The purity of a nucleic acid solution can be determined by
calculating the A260 nm:A280 nm ratio. Pure DNA has
A260 nm/A280 nm ratio of 1.8. The quality of the extracted
DNA was assessed by performing gel electrophoresis using
Agarose gel (Promega) with a concentration of 0.8% for one
hour. The damaged DNA parts were discarded and the rest
of the DNA samples were kept under 20 C for later use.
2.3. PCR
This was done in two stages. The ﬁrst stage involved applying
the PCR in order to identify a certain area of DNA using the
ampliﬁcation of gene B1 for all cases as described by Burg and
his colleagues (Burg et al., 1989). PCR master mix was pre-
pared as described in Table 1. To avoid contamination, we
used negative control that contained all the matrix mix but
not the DNA part. From the seronegative samples, we used
one sample as a negative control and one positive control that
constituted of DNA as part of T. gondii RH strain. The ﬁrst
cycle took 15 min at 95 C to activate the enzymes. In this ﬁrst
cycle, pairs of primers (B1R1 and B1F1) were used (Table 2) to
apply PCR (Roche Company). It involved 39 repeated cycles
with every cycle consisted of 3 steps: denaturation for 30 s at
95 C, annealing for 30 s at the same temperature (at similar
temperature according to the type of the Primer used), and
extension for 30 s at 72 C. At the end of these cycles, a ﬁnal
extension was done for 10 min at 72 C. These steps were
applied in both stages of the PCR and the nested-PCR. The
second stage entailed a nested-PCR, which was performed to
amplify the products of the ﬁrst PCR cycle to obtain clear
DNA using the method of Lee and his colleagues (Lee et al.,
2008). This was done by using 1 ll of the PCR products ofTable 1 Contents of PCR master mix.
Contents 1· 43·
d.H2O 15.8 ll 679.4 ll
10· Buﬀer 2.5 ll 107.5 ll
5 lM F+R Primers mix 2 ll 86 ll
DNA 50 ng/ll 2 ll ––
DNA Polymerase 50 units 0.2 ll 8.6 ll
d.NTPs MIX 0.25 mM 2.5 ll 107.5 ll
Total volume 25 ll 989 llthe ﬁrst cycle (diluted at 1:10) with the rest of PCR Master
Mix contents plus the primers B1R2 and B1F2 at 60 C for
30 s (Table 2).
2.4. Genotyping
This step was carried out on the positive samples that were
obtained using nested PCR for the B1 gene of T. gondii in
order to amplify the SAG2 (Surface Antigen of the intracellu-
lar T. gondii) gene at both 30 and 50 ends separately. We used
PCR reaction mix that contained 5 ll of buffer PCR X10
(100 ml Tris HC1 + 15 mmol MgC12 + 500 mmol KC1 from
Sigma Company) and added to it 1 mmol MgC12, 500 mmol
dNTPs, 10 lmol from each unit of F and R primers of the
Taq DNA polymerase enzyme and 100 nanogram of
Genomic DNA. Initial stage involved PCR testing for
10 min at temperature 95 C, followed by 40 cycles (each cycle
composed of three steps: denaturation for 60 s at temperature
95 C, annealing for 60 s at similar temperature according to
the type of the Primer used, and extension for 60 s at a temper-
ature of 72 C). The Primers used to amplify the 5 end of the
SAG2 gene were SAG2F4 and SAG2R4. The nested-PCR test
was performed by adding 1 ll (diluted 1:10) of the initial PCR
product and used as a source for DNA templates for the sec-
ond cycle (nested-PCR). The same PCR master mix previously
described except that the internal Primers were replaced by
SAG2F4 and SAG2R2 (TIB-MOLBIOL-Germany) at a tem-
perature of 60 C for 60 s (Table 3).
For the ampliﬁcation of the 30 end of SAG2, all the previous
procedures were applied, but the Primers were replaced with
SAG2F3 and SAG2R3 at annealing temperature of 60 C for
30 s. Additionally, similar PCR cycles and nested-PCR were
performed, but the Primers used were replaced by SAG2F2
and SAG2R at annealing temperature of 61 C for 30 s
(Table 4). This was followed by analysing PCR products using
Agarose gel (concentration: 2%).
Genotyping was performed using the Restriction Fragment
Length Polymorphism (PCR-RFLP) (Fuentes et al., 2001).
This involved adding 1.5 ll of Buffer SA (Digestion buffer),
2 ll of Sau3AI enzyme, 10 ll of the PCR products from the
50 end of SAG2 gene and 11.5 ll distilled water. The digestion
was conducted at a temperature of 37 C for three hours, whileTable 3 Primers used for ampliﬁcation for the 50 end of SAG2
gene.
Primers used for ampliﬁcation for the 50 end of SAG2 gene
SAG2F4 50-GACCTCGAACAGGAACAC-30
SAG2R4 50-GCATCAACAGTCTTCGTTGC-30
SAG2F 50-GAAATGTTTCAGGTTGCTGC-30
SAG2R2 50-GCAAGAGCGAACTTGAACAC-30
Table 4 Primers used for ampliﬁcation for the 30 end of SAG2
gene.
Primers used for ampliﬁcation for the 30 end of SAG2 gene
SAG2F3 5
0-TCTGTTCTCCGAAGTGACTCC-30
SAG2R3 50-TCAAAGCGTGCATTATCGC-30
SAG2F2 5
0-ATTCTCATGCCTCCGCTTC-30
SAG2R 5
0-AACGTTTCACGAAGGCACAC-30
200 bp
Lane         1      2      3      4 5     6    7     8  9   10    11   12  13  14    15
Figure 1 Ampliﬁcation of T. gondii B1 gene. Lane 1: Positive
control. Lanes 2 and 3: Negative control. Lanes 6, 8, and 13:
Positive samples. Lanes 4, 5, 7, 9, 10, 11, 12, and 14: Negative
samples. Lane 15: Molecular weight marker 50 bp.
Lane        1     2     3   4    5    6    7    8    9  10  11  12  13   14
100 bp
250 bp
Figure 2 Nested PCR on B1 gene. Lane 1: positive control.
Lanes 2 and 3: negative control. Lanes 4–13: Positive samples.
Lane 14: Molecular weight marker 50 bp.
500bp  
Lane        1     2     3     4      5    6    7      8      9   10    11   12   13   14   15 
Figure 3 First ampliﬁcation of the 50 end of SAG2 locus. Lane 1:
positive control. Lanes 2 and 3: negative control. Lanes 4–14:
Positive samples. Lane 15: Molecular weight marker 100-bp.
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adding 1.5 ll of SL Buffer with 2 ll of Hhal enzyme, 10 ll of
the PCR product of the 30 end SAG2, and 11.5 ll of distilled
water. The digestion was conducted at a temperature of
37 C for three hours. The resulted digestives were run on
Agarose gel (concentration: 25%) using three types of T. gondii
as reference standards and as positive controls. The ﬁrst type
was T. gondii RH strain (type I), the second one was LEG
96-1 (type II), and the third was LEG-NJA (type III). These
were used to identify the genotyping of T. gondii of our
seropositive cases.
2.5. Data analysis
Data were coded and entered into SPSS (version 15). Data
were described using frequencies and percentage.
Correlations between variables were done using Chi-square
with a signiﬁcant cut-off p value of <0.05.
2.6. Ethical consideration
The study was approved by the ethics committee of King Saud
University. Participants were informed of the study aim and
procedures. Consent was obtained and participants were
informed that they are free to join or leave the study at any
stage without giving any justiﬁcation.
3. Results
203 women agreed to take part in our study with a response
rate of 81.2% (203/250). Using ELISA, we found that the
prevalence of Toxoplasma gondii IgG and IgM antibodies
was 32.5% and 6.4%, respectively. The mean age was 32 years
(SD±). 34.9% of those with positive IgG were in their ﬁrst tri-
mester, 32.1% were in the second trimester, and 33% were in
the last trimester of their pregnancy.
PCR test (ﬁrst cycle) revealed 22.2% positive samples
(45/203) and the ampliﬁcation of T. gondii gene B1 with a pro-
duction of a fragment with 196 bp (Fig. 1). The nested-PCR
test for positive samples (second cycle) resulted in an expected
fragment of 97 bp (Fig. 2). Ampliﬁcation of the SAG2 locus in
both 50 and 30 ends of the conﬁrmed cases of T. gondii pro-
duced 241 bp and 221 bp fragments respectively (Figs. 3–6).
We were able to do total genotypic characterization of 80%
of the samples (36 out of 45), which were positive by carrying
out the nested-PCR technique, with two different genomic tar-
gets: B1 and SAG2 genes. From these samples using Agarose
gel electrophoresis, we found that 29 samples (80.6%) were
of genotype II; however 7 samples (19.4%) were of genotype
III. There were 9 samples (only partially characterized) in
which we could not completely identify the parasite genotypes.Six of them (the 30 end) that were digested characterized as
type II (Fig. 7). Four were digested using the enzyme HhaI;
however, we could not determine that it is type II because
the digestion process was not clear enough. The remaining
two were not digested and considered as either type I (RH
strain) or III (non-type II). In three samples, the 50 end was
only ampliﬁed and two of them were Sau3AI digested
(Fig. 8) and again, here, it was not possible to characterize
them as type III because digestion process was not clear;
Lane 1 2 3 4 5 6 7 8 9 10 11
250 bP
Figure 4 Second ampliﬁcation of the 50 end of SAG2 locus. Lane
1: positive control. Lanes 2 and 3: negative control. Lanes 4–10:
some positive samples. Lane 11: Molecular weight marker 50-bp.
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
500 bp
Figure 5 First ampliﬁcation of the 30 end of SAG2 locus. Lane 1:
positive control. Lane 2: negative control. Lane 3: negative
control. Lanes 4–14: some positive samples. Lane 15: Molecular
weight marker 100-bp.
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14
250
Figure 6 Second ampliﬁcation of the 30 end of SAG2 locus. Lane
1: positive control. Lane 2: negative control. Lane 3: negative
control. Lanes 4–13: some positive samples. Lane 14: Molecular
weight marker 50 bp.
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
250
Figure 7 HhaI Restriction digestion of the 30 end ampliﬁcation
products. Lane 1: type I strain. Lane 2: Type II strain. Lane 3:
Type III strain. Lanes 4–10, 12, 13, and 14: strains from clinical
samples of type II strain. Lane 11: sample of nontype II strain.
Lane 15: Molecular weight marker 50 bp.
250
Lane 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Figure 8 Sau3AI Restriction digestion of the 50 end ampliﬁca-
tion products. Lane 1: type I strain. Lane 2: Type II strain. Lane 3:
Type III strain. Lanes: 4–10, 12, 13, and 14: strains from clinical
samples of nontype III strains.
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either type I or II (non-type III).
4. Discussion
This study showed that T. gondii was prevalent among Saudi
pregnant women (32.5% for IgG and 6.4% for IgM). The
majority of cases were of genotype II of T. gondii. World-
wide, T. gondii prevalence in human varies from region to
region with rates range from less than 10% to over 90%
(Bouratbine et al., 2001; Torgerson and Mastroiacovo,
2013). For example, a study conducted among ante-natal care
patients in Saudi Arabia showed higher rate of IgG (38%)
than our ﬁnding; however, the researchers did not ﬁnd IgM
among their sample (Almogren, 2011). Another studyconducted in Qatar with almost similar results to our ﬁndings
showed that 35.1% and 5.2% of pregnant women tested pos-
itive for IgG and IgM, respectively (Abu-Madi et al., 2010).
A literature review showed that high prevalence exists in
Latin America, parts of Eastern/Central Europe, the Middle
East, parts of south-east Asia and Africa. However, a trend
towards lower sero-prevalence is observed in many European
countries and the USA. Authors suggested that there is an
over-representation of certain countries such as Iran, while
information from other, geographically larger, countries may
be limited (Pappas et al., 2009).
This variation in the sero-prevalence rate might be
explained by several reasons. The presence of speciﬁc IgM is
generally suggested to be associated with acute infection.
However, this may not be the case in toxoplasmosis, as the
continuation of IgM for several months in the sera may inter-
fere in calculating the time of exposure (Pelloux et al., 1997).
Therefore, different timing of measuring the sero-positivity
might give different results, which in turn depends on the stage
of the infection of T. gondii whether acute or chronic period of
the disease. Moreover, regional variation of prevalence has
been attributed to climate, cultural differences in the amount
and type of raw meat consumed, and the increased consump-
tion of meat from animal’s farmed indoors and frozen meat.
650 J. Alghamdi et al.Our present study focuses on the prevalence and genotyping of
T. gondii; however, we will report the role of socio-
demographic proﬁle and life-style in the occurrence of such
infection in another paper.
Another issue in collectively evaluating what sero-
prevalence rates provided to us is the difference in diagnostic
methods used. Several methods are available which ﬁnally
allow diagnosing the stage of infection. However, value of
these tests in diagnosing the acute T. gondii infections can be
questioned particularly from developing countries (Singh and
Pandit, 2004). Although the detection of IgM antibodies is
the most commonly used method for serological diagnosis of
acute infections, yet it has some disadvantages. Moreover,
the IgM-ISAGA test which is considered standard test remains
positive for up to 12 months after primary infection
(bioMe´rieux, 2000). Therefore, it may be difﬁcult to interpret
the single point IgM positive results in women who tested dur-
ing the different trimesters of their pregnancy. Indeed, it is a
measure of the accumulated exposure during a person’s life-
time in a particular social setting.
Another variation exists also in the genotyping of T. gondii.
Moreover, assumption about the global evolution of
T. gondii has led to a worldwide effort to investigate genetic
diversity within this interesting organism. It has been described
as a parasite with a low genetic diversity and a clonal popula-
tion structure (Darde´, 2008). While isolates of T. gondii were
historically considered to be highly comparable, molecular
analysis revealed that they exhibit very marked genotyping,
notably in North America and Europe, where three
predominant lineages, known as types I, II, and III, comprise
the vast majority of isolates (Sibley and Ajioka, 2008). In our
study, type II was the most common type. Most reports
propose that the high prevalence of type II strains in humans
is caused by the high prevalence of that strain in animals
(Fuentes et al., 2001). Genotype analysis may identify the
source of an infection. This analysis will also assist in
understanding the pathogenesis of T. gondii infection and its
epidemiology, and in planning preventive strategies.
Researchers suggested that the majority of human infec-
tions that have been studied in North America and Europe
are caused by type II strains (Sibley et al., 2009). However,
using PCR-RFLP method, recombinant strains representing
mixtures of the three clonal types were also occasionally found
(approx. 5%). These isolates, presenting different mixtures of
classical alleles can be considered as recombinant genotypes:
‘‘Atypical’’, ‘‘unusual’’, ‘‘non-archetypal’’ or ‘‘exotic’’ strains
(Darde´, 2008).
Most genotypes are locale-speciﬁc, but some are found
across continents and are closely related to each other, indicat-
ing a recent radiation of a pandemic genotype (Lehmann et al.,
2006).5. Conclusion
Deﬁning the population structure of T. gondii from Saudi
Arabia has important implications for transmission, immuno-
genicity, pathogenesis, and in planning preventive strategies.
Relationship between such variation in structure and disease
manifestation in pregnant women is still difﬁcult to assess
due to the role of host immune status and genetic background
on the control of infection, and of other parasitic features suchas the infecting dose or parasite stage. The situation for the
‘‘new’’ genotypes is yet more complex, due to their diversity
and the combination of genes.
Our ﬁnding of the genotyping of T. gondii might facilitate
and inform future studies on comparative genomics and iden-
tiﬁcation of genes that control important biological pheno-
types including pathogenesis and transmission among Saudi
women.
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